> Detailanzeige

Brivio, Erica; Lopez-Yurda, Marta; Ownes, Cormac; Díaz de Heredia, Cristina; Bielorai, Bella; Rossig, Claudia; van der Velden, Vincent; Ammerlaan, Anneke C.J.; van der Sluis, Inge M.; Den Boer, Monique L.; Chen, Ying; Sleight, Barbara; Brethon, Benoit; Nysom, Karsten; Stary, Jan; Øra, Ingrid; Chen-Santel, Christiane; Vinti, Luciana; Locatelli, Franco; Zwaan, Christian Michel

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study
  • Beteiligte: Brivio, Erica; Lopez-Yurda, Marta; Ownes, Cormac; Díaz de Heredia, Cristina; Bielorai, Bella; Rossig, Claudia; van der Velden, Vincent; Ammerlaan, Anneke C.J.; van der Sluis, Inge M.; Den Boer, Monique L.; Chen, Ying; Sleight, Barbara; Brethon, Benoit; Nysom, Karsten; Stary, Jan; Øra, Ingrid; Chen-Santel, Christiane; Vinti, Luciana; Locatelli, Franco; Zwaan, Christian Michel
  • Erschienen: American Society of Hematology, 2019
  • Erschienen in: Blood
  • Sprache: Englisch
  • DOI: 10.1182/blood-2019-122411
  • ISSN: 0006-4971; 1528-0020
  • Schlagwörter: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p /> <jats:p>Background:</jats:p> <jats:p>Inotuzumab ozogamicin (InO) is an anti-CD22 antibody linked to calicheamicin, approved for relapsed/refractory (R/R) CD22+ B-cell precursor adult acute lymphoblastic leukemia (BCP-ALL) at starting dose of 1.8 mg/m2/course. A phase I study in pediatric patients (pts) is being performed and sponsored by Erasmus MC in collaboration with Pfizer, registered in the Dutch Trial Registry (NTR57360).</jats:p> <jats:p>Study design:</jats:p> <jats:p>Children aged 1-18 years with R/R CD22+ BCP-ALL (ALL) were included after IRB approval and informed consent was obtained. Key inclusion criteria consisted of M2/M3 marrow and adequate liver and kidney function. The study aimed to determine the recommended phase 2 dose (RP2D) of single agent InO; secondary objectives included safety, response and pharmacokinetics (PK). Dose escalation followed the Rolling-6 design, with dose-limiting toxicity (DLT) evaluation during course 1 and defined as delay in hematological (hem) recovery after D42 in responding pts and grade (gr) ≥3 non-hem toxicities &gt;48 hours (or &gt;7 days for liver tests). DL1 was 1.4 mg/m2 (0.6-0.4-0.4 mg/m2). Overall response rate (ORR) was defined as CR, CRp (ANC &gt;0.5x10.9/l but PLT ≤50x10.9/l) and CRi (ANC ≤0.5x10.9/l and/or PLT ≤50,000/µL). Central minimal residual disease (MRD) analysis by flow cytometry and RQ-PCR was considered negative if &lt;0.01% or &lt;1x10-4. PK samples were measured with validated HPLC/MS/MS methods.</jats:p> <jats:p>In the first cohort, 2 patients at DL2 experienced a DLT per protocol definition, however these toxicities were considered non-dose limiting; both pts achieved CR. An IRB-approved amendment allowed repeating the DL1 and DL2 DLT assessment in a 2nd cohort. Survival analysis used the Kaplan-Meier method. Results are based on a database snapshot on June 22, 2019.</jats:p> <jats:p>Results:</jats:p> <jats:p>25 pts were enrolled (Jan 2017-Apr 2019), median age 11 years (range 1.7-16.9); 3 (12%) were refractory, 15 (60%) ≥2nd relapsed ALL and 7 (28%) 1st relapse post-HSCT (median 2 prior treatment regimens, range 2-7). Eleven (44%) pts were previously transplanted; median baseline WBC 3.5 x109/L (range 0.2-8.6). In total, 46 courses of InO were administered (median 2/pt, range, 1-4).</jats:p> <jats:p>23 of 25 treated pts were DLT-evaluable. In the first cohort, 1/6 and 2/5 pts at DL1 and DL2 experienced a DLT per protocol definition (transaminases elevation and no hem. recovery), but considered non-dose limiting. After the IRB-approved amendment, in the 2nd cohort, 0/6 and 1/6 pts in DL1 and DL2 had a DLT (no hem recovery).</jats:p> <jats:p>All 25 pts had at least 1 adverse event (AE) in Course 1 [24 gr 3-4]: 20 pts experienced ≥1 gr 3-4 hem AE, 15 pts a gr 3-4 non-hem AE (13 treatment-related, mainly febrile neutropenia/infections and lab abnormalities). Gr 3-4 transaminases elevation related to InO was seen in 3 pts (12%) and bilirubin in 2 (8%) in Course 1.</jats:p> <jats:p>2 cases of VODs (gr 3-4) were reported after InO, both after follow-up chemotherapy (including HD-MTX) for R/R disease. None of these pts received any HSCT.</jats:p> <jats:p>After Course 1, 75% of pts responded at DL1 and 85% at DL2; ORR 80% (CR n=15, CRp n=1, CRi n=4). MRD was available in 19/20 responding pts: 15 (79%) reached MRD-negative CR as best response (6/9 at DL1 and 9/10 at DL2). Consolidation treatment with HSCT (n=6) or CAR-T cells (n=2) was given a median time of 61 days (range 23-125) after the last InO dose. None of these pts had been previously transplanted.</jats:p> <jats:p>The median follow-up for responding pts was 13.3 months (mos), median duration of response 8 mos (range 1.1-14.0). EFS was 66.7% (95% CI 47.9-93.0) and 33.4% (95% CI: 16.5 − 67.4), while the OS 63.3% (95% CI: 45.8−87.6) and 38.7% (95% CI: 21.3 - 70.4) at 6 and 12 mos, respectively.</jats:p> <jats:p>During follow-up, at relapse 13 pts had material available and sufficient ALL cells for reliable CD22 analysis: 2/13 showed CD22-negativity.</jats:p> <jats:p>After multiple doses, observed Ino medium maximum concentrations in DL1 (n=9) and DL2 (n=5) were 217 and 246 ng.hr/mL, comparable to the simulated adult concentration 234 ng.hr/mL at 1.8 mg/m2 dose.</jats:p> <jats:p>Conclusions:</jats:p> <jats:p>InO was well tolerated and showed remarkable activity in these heavily pretreated pts. The RP2D was established at 1.8 mg/m2/course (0.8-0.5-0.5 mg/m2), confirming the dose used in adults. Two cases of VOD were recorded after follow-up chemotherapy. The ORR was 80%; 79% of responding pts had MRD-negative CR, with 40% of pts being alive after 1 year of follow-up. A phase II single agent study in R/R pediatric ALL is ongoing and a Phase 1 of InO in combination with chemotherapy will start soon.</jats:p> <jats:sec> <jats:title>Disclosures</jats:title> <jats:p>Díaz de Heredia: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Rossig:Amgen, Celgene,EUSA Pharma, Genetech, Novartis, Roche: Other: advisory board; BMS, Pfizer, Roche: Other: speaker honoraria. van der Velden:Amgen: Honoraria, Research Funding; Jansen: Research Funding; BD Biosciences: Research Funding. van der Sluis:medac: Consultancy; jazz farmaceuticals: Consultancy. Chen:Pfizer Inc.: Employment. Sleight:Pfizer: Employment, Equity Ownership. Nysom:Bayer: Membership on an entity's Board of Directors or advisory committees, Other: Teaching and lectures. Øra:Bayer: Membership on an entity's Board of Directors or advisory committees. Locatelli:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; bluebird bio: Consultancy; Miltenyi: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bellicum: Consultancy, Membership on an entity's Board of Directors or advisory committees. Zwaan:Novartis: Consultancy; Janssen: Consultancy; Jazz pharmaceuticals: Other: Travel support; Daiichi Sankyo: Consultancy; Servier: Consultancy; Pfizer: Consultancy, Research Funding; BMS: Research Funding; Celgene: Consultancy, Research Funding; Sanofi: Consultancy; Roche: Consultancy; Incyte: Consultancy.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang